Literature DB >> 27116008

Evaluation of the Bio-Rad Dx CT/NG/MG® assay for simultaneous detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium in urine.

D Ursi1, T Crucitti2, H Smet2, M Ieven3.   

Abstract

We evaluated the performance of the Bio-Rad real-time Dx CT/NG/MG® assay for detection of C. trachomatis, N. gonorrhoeae and M. genitalium on a collection of 441 urine samples from sexually transmitted infections, or travellers consultations and from anonymous sperm donors that were previously analysed with the Abbott RealTime CT/NG assay. Samples positive for C. trachomatis or N. gonorrhoeae with the Abbott assay had all previously been confirmed with an in-house real-time PCR assay. Samples positive for M. genitalium with the Bio-Rad assay were subsequently analysed by an in-house real-time PCR. On a total of 441 urines, 104 samples were positive for C. trachomatis, 12 were positive for N. gonorrhoeae and seven were positive for M. genitalium. After retesting of discrepant results, the test results were completely concordant, resulting in a calculated sensitivity and specificity of the Bio-Rad assay of 98.1 % and 100 % for C. trachomatis and of 91.7 % and 100 % for N. gonorrhoeae. Results for M. genitalium with the Bio-Rad assay were also concordant with the results of an in house PCR. We also evaluated the performance of automated nucleic acid extractions of urine samples with the NucliSENS easyMAG (bioMérieux) compared to the manual DNA extraction prescribed by the insert of the kit. The easyMAG extraction gave lower Ct values, relieved inhibition and had a lower hands-on time.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27116008     DOI: 10.1007/s10096-016-2646-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  Review of use of a new rapid real-time PCR, the Cepheid GeneXpert® (Xpert) CT/NG assay, for Chlamydia trachomatis and Neisseria gonorrhoeae: results for patients while in a clinical setting.

Authors:  Charlotte A Gaydos
Journal:  Expert Rev Mol Diagn       Date:  2014-01-23       Impact factor: 5.225

2.  The first performance report for the Bio-Rad Dx CT/NG/MG assay for simultaneous detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium in urogenital samples.

Authors:  Chloé Le Roy; Isabelle Le Hen; Maïthé Clerc; Véronique Arfel; Françoise Normandin; Cécile Bébéar; Bertille de Barbeyrac
Journal:  J Microbiol Methods       Date:  2012-03-15       Impact factor: 2.363

3.  In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains.

Authors:  Jørgen Skov Jensen; Prabhavathi Fernandes; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

4.  Validation of a laboratory-developed real-time PCR protocol for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine.

Authors:  M J Hopkins; L J Ashton; F Alloba; A Alawattegama; I J Hart
Journal:  Sex Transm Infect       Date:  2010-06       Impact factor: 3.519

5.  Development of a rotor-gene real-time PCR assay for the detection and quantification of Mycoplasma genitalium.

Authors:  Etienne E Müller; Johanna M E Venter; Mahlape P Magooa; Charles Morrison; David A Lewis; Sue Napierala Mavedzenge
Journal:  J Microbiol Methods       Date:  2011-12-29       Impact factor: 2.363

6.  Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance.

Authors:  Jørgen S Jensen; Catriona S Bradshaw; Sepehr N Tabrizi; Christopher K Fairley; Ryoichi Hamasuna
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079

7.  A real-time quadriplex PCR assay for the diagnosis of rectal lymphogranuloma venereum and non-lymphogranuloma venereum Chlamydia trachomatis infections.

Authors:  C-Y Chen; K H Chi; S Alexander; C A Ison; R C Ballard
Journal:  Sex Transm Infect       Date:  2008-02-18       Impact factor: 3.519

8.  Direct detection of macrolide resistance in Mycoplasma genitalium isolates from clinical specimens from France by use of real-time PCR and melting curve analysis.

Authors:  Arabella Touati; Olivia Peuchant; Jorgen S Jensen; Cécile Bébéar; Sabine Pereyre
Journal:  J Clin Microbiol       Date:  2014-02-26       Impact factor: 5.948

Review 9.  Mycoplasma genitalium: a review.

Authors:  G M Daley; D B Russell; S N Tabrizi; J McBride
Journal:  Int J STD AIDS       Date:  2014-02-11       Impact factor: 1.359

10.  Mycoplasma genitalium testing pattern and macrolide resistance: a Danish nationwide retrospective survey.

Authors:  Kirsten Salado-Rasmussen; Jørgen Skov Jensen
Journal:  Clin Infect Dis       Date:  2014-04-11       Impact factor: 9.079

  10 in total
  4 in total

1.  Comparison between DiaPlexQ™ STI6 and GeneFinder™ STD I/STD II multiplex Real-time PCR Kits in the detection of six sexually transmitted disease pathogens.

Authors:  Hee Jae Huh; Chang-Seok Ki; Sun Ae Yun; Jungsoo Lee; Gwi Young Oh; Nam-Sihk Lee; Young Ho Yoon; Nam Yong Lee
Journal:  J Clin Lab Anal       Date:  2018-11-02       Impact factor: 2.352

2.  Should we screen for the sexually-transmitted infection Mycoplasma genitalium? Evidence synthesis using a transmission-dynamic model.

Authors:  Ruthie Birger; John Saunders; Claudia Estcourt; Andrew John Sutton; Catherine H Mercer; Tracy Roberts; Peter J White
Journal:  Sci Rep       Date:  2017-11-23       Impact factor: 4.379

Review 3.  The Laboratory Diagnosis of Neisseria gonorrhoeae: Current Testing and Future Demands.

Authors:  Thomas Meyer; Susanne Buder
Journal:  Pathogens       Date:  2020-01-31

4.  Prevalence of Mycoplasma genitalium in men with urethritis in a large public hospital in Brussels, Belgium: An observational, cross-sectional study.

Authors:  Agnès Libois; Marie Hallin; Tania Crucitti; Marc Delforge; Stéphane De Wit
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.